Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 8/20 | 0.39 |
| ▸ | BCR | P11274 | 8/20 | 0.39 |
| ▸ | BRAF | P15056 | 8/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436584 | 0.92 | GPR142 (0.42) | GPR142ABL1BCRBRAFFLT1 | |
| SCHEMBL13436576 | 0.91 | GPR142 (0.39) | GPR142ABL1BCRBRAFFLT1 | |
| SCHEMBL12465242 | 0.90 | GPR142 (0.52) | GPR142ABL1BCRBRAF | |
| SCHEMBL13436580 | 0.89 | BRAF (0.42) | GPR142ABL1BCRBRAF | |
| SCHEMBL12465279 | 0.89 | GPR142 (0.44) | GPR142ABL1BCRBRAFFLT1 | |
| SCHEMBL13436581 | 0.88 | BRAF (0.44) | GPR142ABL1BCRBRAF | |
| SCHEMBL13436291 | 0.88 | DDR1 (0.46) | ABL1BCRBRAF | |
| SCHEMBL13436589 | 0.86 | ABL1 (0.42) | ABL1BCR | |
| SCHEMBL2364698 | 0.86 | GPR142 (0.44) | GPR142ABL1BCRBRAF | |
| SCHEMBL13436656 | 0.86 | GPR142 (0.42) | GPR142ABL1BCRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | claimed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2350052-A2 | ANTIPROLIFERATIVE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GPR142 3944/4885ABL1 234/4885BCR 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.